SEC Form 4 · accession 0001764013-26-000069
Immunovant, Inc. · IMVT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Atul Pande
Director
Period of report
Jun 15, 2026
Accepted (ET)
Jun 16, 2026 · 4:03 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001764013
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 15, 2026 | M | 1,500 | $8.43 | A | 118,231 | D | |
| Common Stock | Jun 15, 2026 | S | 1,500 | $34.02 | D | 116,731 | D | |
| Common Stock | holding | — | — | — | 20,000 | I | By Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3,F2 | $8.43 | Jun 15, 2026 | M | 1,500 | D | — | Nov 19, 2029 | Common Stock | 1,500 | 69,681 | D |
Explanation of responses
- F1Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025.
- F2Reflects an award of stock options to purchase Common Shares that is fully vested.
- F3The Form 4 filed on May 20, 2026 inadvertently disclosed the total of all remaining options held by the Reporting Person following the reported transaction in this specific option. This total correctly reflects only the remaining options for the specific option.